VectivBio
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
VectivBio was a Basel, Switzerland-based clinical-stage biopharmaceutical company pioneering transformational treatments for severe rare gastrointestinal diseases. Formed in 2019 as a spinout from Therachon (a biotech acquired by Pfizer), it was led by founder and CEO Luca Santarelli. Its lead investigational asset was apraglutide, a GLP-2 analog in Phase III trials for short bowel syndrome with intestinal failure (SBS-IF), a potentially fatal condition affecting an estimated 18,000 adult patients in the US, Europe and Japan.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Formed
VectivBio was formed in Basel as a spinout from Therachon, which had been acquired by Pfizer, to develop transformational medicines for serious rare conditions.
- Nasdaq listing
VectivBio listed on Nasdaq (VECT) and advanced apraglutide through late-stage trials for short bowel syndrome with intestinal failure.
- Acquired by Ironwood
Ironwood Pharmaceuticals announced the acquisition of VectivBio for $17.00 per share in an all-cash deal valued at approximately $1 billion, gaining apraglutide, which Ironwood said could reach $1 billion in peak net sales. The merger was completed in December 2023, with remaining VectivBio shares converted to $17.00 per share in cash.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.